Despite intensive research efforts on AD, until now, the FDA (Food and Drug Administration, USA) has approved treatments mostly based on cholinergic drugs to compensate for the loss of cholinergic neurons, namely acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitors, such as tacrine, donepezil, rivastigmine, galantamine, but also one glutamatergic drug (memantine), a N-methyl-D-aspartate (NMDA) receptor antagonist [8]. Here, BCHE is linked to Alzheimer disease.